

Organized by



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

9th Congress on Lung Cancer

Barcelona, November 17th and 18th, 2011

Registrations: www.doctaforum.com/gecp

CHAIR

Rafael Rosell
*ICO, Hospital Univ. Germans Trias i Pujol,
Badalona (Barcelona)*

Under the Auspices of:

SEOM
Sociedad Española
de Oncología Médica

ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE
European Society for Medical Oncology

Thursday, 17th November 2011

SESSION 1: EARLY NSCLC

CHAIRS: Florentino Hernando-Trancho, *Hospital Clínico Univ. San Carlos, Madrid*
Miquel Tarón, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

10:30 - 10:35 Introduction

Miquel Tarón, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

10:35 - 10:50 Predictive gene signature

Ramón García-Escudero, *Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid*

10:50 - 11:05 Gene signatures in early NSCLC

Miquel Tarón, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

11:05 - 11:20 Modern approaches to customizing adjuvant chemotherapy

Michel van den Heuvel, *Netherlands Thoracic Institute -Antoni van Leeuwenhoek Hospital, Amsterdam, Holland*

11:20 - 11:35 Molecular analysis of survival signaling pathways from the NATCH trial: A Trans-Atlantic Collaboration

Fadlo R. Khuri, *Emory University, Atlanta (Georgia), USA*

11:35 - 11:40 Conclusions

Florentino Hernando-Trancho, *Hospital Clínico Univ. San Carlos, Madrid*

SESSION 2: PATHOLOGY AND LUNG CANCER BIOLOGY

CHAIRS: Susana Benlloch, *USP Institut Dexeus, Pangaea Biotech, Barcelona*
Javier de Castro, *Hospital Univ. La Paz, Madrid*

11:40 - 11:45 Introduction: relevance of translational research

Javier de Castro, *Hospital Univ. La Paz, Madrid*

11:45 - 12:00 Molecular advances in lung cancer pathology

Santiago Ramón y Cajal, *Hospital Univ. Vall d'Hebron, Barcelona*

12:00 - 12:15 BRAF mutations in NSCLC

Antonio Marchetti, *University-Foundation, Chiety, Italy*

12:15 - 12:30 ALK, LKB1 and P130 assessment

M^a Luisa Botero, *USP Institut Dexeus, Pangaea Biotech, Barcelona*

12:30 - 12:45 p53 mutations in lung cancer

Miguel Á. Molina, *USP Institut Dexeus, Pangaea Biotech, Barcelona*

12:45 - 13:00 Endothelial circulating cells and microparticles in lung cancer

Tania C. Fleitas, *Hospital Univ. La Fe, Valencia*

13:00 - 14:15 Lunch

Barcelona, November 17th and 18th, 2011

SESSION 3: DISCOVERIES IN CANCER BIOLOGY

CHAIRS: Montserrat Sánchez-Céspedes, *Instituto de Investigación Biomédica de Bellvitge, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*
Miquel Tarón, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

14:15 - 14:30 **Mutation screening and biological characterization of BRG1 and other tumor suppressor genes in lung cancer**
Montserrat Sánchez-Céspedes, *Instituto de Investigación Biomédica de Bellvitge, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*

14:30 - 14:45 **Keynote Lecture: NF- κ B in FAS signaling pathway in tumors with EGFR mutations**
Trevor G. Bivona, *University of San Francisco, California, USA*

14:45 - 15:15 **Genes involved in chromatin remodeling complex as determinants of sensitivity to ALK and EGFR inhibitors**
René Bernards, *Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Holland*

15:15 - 15:30 **AEG-1 and BRCA1 as determinants of outcome to erlotinib in EGFR-mutated NSCLC**
Miquel Tarón, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

15:30 - 15:45 *Break*

SESSION 4: CUSTOMIZED CLINICAL TRIALS

CHAIRS: Carlos Camps, *Hospital General Universitario, Valencia*
Bartomeu Massutí, *Hospital General Universitario, Alicante*

Introduction
Bartomeu Massutí, *Hospital General Universitario, Alicante*

15:45 - 16:00 **EURTAC**
Luis Paz-Ares, *Hospital Univ. Virgen del Rocío, Sevilla*

16:00 - 16:15 **SCAT**
José M. Sánchez, *Centro Oncológico M.D. Anderson International España, Madrid*

16:15 - 16:30 **BREC**
Carlos Camps, *Hospital General Universitario, Valencia*

16:30 - 16:45 **BREC-China**
Jia Wei, *Drum Tower Hospital, Nanjing, China*

16:45 - 17:00 **Olaparib+gefitinib**
Rosario García-Campelo, *Complejo Hospitalario Universitario, A Coruña*

17:00 - 17:15 **Bevacizumab**
Oliver Gautschi, *Bern University Hospital, Bern, Switzerland*

17:15 - 17:40 *Coffee Break*

CLINICAL WORKSHOP

CHAIRS: Carlos Camps, *Hospital General Universitario, Valencia*
Manuel Dómine, *Fundación Jiménez Díaz, Madrid*
Dolores Isla, *Hospital Clínico Univ. Lozano Blesa, Zaragoza*

- 17:40 - 17:50 **Lung cancer in never-smokers: differential issues**
José M. Trigo, *Hospital Clínico Univ. Virgen de la Victoria, Málaga*
- 17:50 - 18:00 **Different endpoints with targeted therapies**
Manuel Cobo, *Hospital Univ. Carlos Haya, Málaga*
- 18:00 - 18:10 **Optimal techniques for early detection of response**
Alfredo Sánchez, *Hospital Provincial de Castellón, Castellón*
- 18:10 - 18:20 **New drugs, new toxicities**
Ruth Porta, *ICO, Hospital Univ. Dr. Josep Trueta, Girona*
- 18:20 - 18:30 **Treatment strategy for advanced squamous carcinoma**
Margarita Majem, *Hospital de la Santa Creu i Sant Pau, Barcelona*
- 18:30 - 18:40 **Selection of patients for maintenance treatment**
Ana Blasco, *Hospital General Universitario, Valencia*
- 18:40 - 18:50 **Treatment for patients resistant to EGFR-TKIs**
Ramón Palmero, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*
- 18:50 - 19:00 **The REASON study**
Bartomeu Massutí, *Hospital General Universitario, Alicante*
- 19:00 - 19:10 **Outcomes to pemetrexed in advanced NSCLC: An overview of recent findings**
Santiago Ponce Aix, *Hospital Univ. 12 de Octubre, Madrid*
- 19:10 - 19:20 **Discussion**
Carlos Camps, *Hospital General Universitario, Valencia*
Manuel Dómine, *Fundación Jiménez Díaz, Madrid*
Dolores Isla, *Hospital Clínico Univ. Lozano Blesa*

Barcelona, November 17th and 18th, 2011

Friday, 18th November 2011

08:00 - 08:30 **SLCG Plenary Session**

08:30 - 09:00 **Plenary Lecture**

Rafael Rosell, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

SESSION 5: APPLICABILITY OF TRANSLATIONAL RESEARCH

CHAIRS:

Adolfo G. Favaretto, *University Hospital, Padua, Italy*

Miquel Tarón, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

09:00 - 09:15 **mRNA expression of genes involved in the EGFR and NF-kB pathways**

Santiago Viteri, *USP Institut Dexeus, Pangaea Biotech, Barcelona*

09:15 - 09:30 **NF-kB inhibitors and RAS signalling**

Haian Fu, *Emory University, Atlanta (Georgia), USA*

09:30 - 09:45 **The refined BRCA1 model in cisplatin-treated patients**

Laura Bonanno, *Istituto Oncologico Veneto, Padua, Italy*

09:45 - 10:00 **Circulating tumor cells**

Andreas-Claudius Hoffmann, *West German Cancer Center, Essen, Germany*

10:00 - 10:15 **EGFR in Latin America**

Andrés F. Cardona, *Institute of Oncology, Fundación Santa Fe de Bogotá, Colombia*

10:15 - 10:30 **The TOFEM registry**

Margarita Majem, *Hospital de la Santa Creu i Sant Pau, Barcelona*

10:30 - 10:45 **Molecular predictive markers for response to bevacizumab:
the role of the AMP kinase pathway**

Stefano Indraccolo, *Istituto Oncologico Veneto - IRCCS, Padua, Italy*

10:45 - 11:00 **Keynote Lecture: FGFR1 amplification and other targetable alterations in
squamous cell carcinoma**

Roman Thomas, *Dana Farber Cancer Institute, Harvard Medical School, Boston (Massachusetts), USA*

11:00 - 11:20 *Coffee Break*

SESSION 6: Chemoradiotherapy

CHAIRS:

Wilfried Eberhardt, *West German Cancer Center, Essen, Germany*

Ferran Guedeà, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*

11:20 - 11:35 **Trimodality in stage III NSCLC**

Wilfried Eberhardt, *West German Cancer Center, Essen, Germany*

11:35 - 11:50 **Progress in chemoradiotherapy studies**

Pilar Garrido, *Hospital Univ. Ramón y Cajal, Madrid*

11:50 - 12:05 **Potential role for customized and targeted therapies in the NSCLC neoadjuvant setting**

Diego Márquez-Medina, *Hospital Arnau de Vilanova, Lleida*
Yolanda García, *Corporació Sanitària Parc Taulí, Sabadell (Barcelona)*

12:05 - 12:20 **Translational research in stage III NSCLC**

Joana Spiekermann, *West German Cancer Center, Essen, Germany*

12:20 - 12:30 **Conclusions**

Josep Jové, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

9th Congress on Lung Cancer

SESSION 7: SCLC

CHAIR: Manuel Dómine, *Fundación Jiménez Díaz, Madrid*

12:30 - 12:45 **Optimal approach for limited disease**

Corinne Finn, *The Christie NHS Foundation Trust, Manchester, United Kingdom*

12:45 - 13:00 **Treatment of metastatic SCLC**

Fiona H. Blackhall, *The Christie NHS Foundation Trust, Manchester, United Kingdom*

13:00 - 13:15 **Molecular research in SCLC: an empty field?**

Luciano Wannesson, *Oncology Institute of Southern Switzerland, Bellinzona, Switzerland*

13:15 - 13:30 **Conclusions**

Manuel Dómine, *Fundación Jiménez Díaz, Madrid*

SESSION 8: SPECIAL CASES

CHAIRS: Rolf A. Stahel, *University Hospital, Zurich, Switzerland*
Alain Vergnenègre, *Cluzeau University Hospital, Limoges, France*

13:30 - 13:45 **Mesothelioma: state of the art and projects**

Rolf A. Stahel, *University Hospital, Zurich, Switzerland*

13:45 - 14:00 **Molecular research in mesothelioma: an empty field?**

Eric Carcereny, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

14:00 - 14:15 **Management of elderly patients**

Alain Vergnenègre, *Cluzeau University Hospital, Limoges, France*

14:15 - 15:15 *Lunch*

SESSION 9: TARGETED THERAPIES AND NOVEL AGENTS

CHAIRS: Fernando Barata, *Centro Hospitalario Coimbra, Coimbra, Portugal*
Felipe Cardenal, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*

Introduction

Felipe Cardenal, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*

15:15 - 15:30 **State of the art of clinical trials with novel agents**

Enriqueta Felip, *Hospital Univ. Vall d'Hebron, Barcelona*

15:30 - 15:45 **The role of the ETOP in clinical trials**

Rolf A. Stahel, *University Hospital, Zurich, Switzerland*

15:45 - 15:55 **Cost-efficacy management in the use of EGFR TKIs**

Ana Clopès, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*

15:55 - 16:10 **Conclusions**

Fernando Barata, *Centro Hospitalario Coimbra, Coimbra, Portugal*

Barcelona, November 17th and 18th, 2011

SESSION 10: SLCG CLINICAL TRIALS

CHAIRS: Enric Carcereny, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*
Alain Vergnenègre, *Cluzeau University Hospital, Limoges, France*

16:10 - 16:15 **PHALCIS**
José M. Sánchez, *Centro Oncológico M.D. Anderson International España, Madrid*

16:15 - 16:25 **ANGIOMET**
Eloísa Jantus, *Hospital General Universitario, Valencia*

16:25 - 16:45 **TARZO**
Noemí Reguart, *Hospital Clínic Universitari, Barcelona*

16:45 - 16:55 **RENO**
Mariano Provencio, *Hospital Univ. Puerta de Hierro, Majadahonda (Madrid)*

16:55 - 17:15 **LUNGSCAPE**
Fiona H. Blackhall, *The Christie NHS Foundation Trust, Manchester, United Kingdom*
Keith Kerr, *Aberdeen University Medical School, Aberdeen, United Kingdom*

Venue

Hotel Meliá Barcelona
50 Sarriá Av.
08029 Barcelona (Spain)

Language

Lectures will be delivered in English or Spanish

Organizing & Scientific Committee

Carlos Camps, *Hospital General Universitario Valencia*
Felipe Cardenal, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*
Javier de Castro, *Hospital Universitario La Paz, Madrid*
Manuel Cobo, *Hospital Universitario Carlos Haya, Málaga*
Manuel Dómine, *Fundación Jiménez Díaz, Madrid*
Rosario García Campelo, *Complejo Hospitalario Universitario, A Coruña*
Florentino Hernando-Trancho, *Hospital Clínico Universitario San Carlos, Madrid*
Dolores Isla, *Hospital Clínico Universitario Lozano Blesa, Zaragoza*
Eloisa Jantús, *Hospital General Universitario, Valencia*
Margarita Majem, *Hospital de la Santa Creu i Sant Pau, Barcelona*
Bartomeu Massutí, *Hospital General Universitario, Alicante*
Luis Paz Ares, *Hospital Universitario Virgen del Rocío, Seville*
Mariano Provencio, *Hospital Universitario Puerta de Hierro, Majadahonda (Madrid)*
Noemí Reguart, *Hospital Clínic Universitari, Barcelona*
Rafael Rosell, *ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)*
José Javier Sánchez, *Universidad Autónoma de Madrid*
José Miguel Sánchez, *Centro Oncológico MD Anderson International, Madrid*
Miquel Taron, *ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)*

Credits

Accredited by the European Society for Medical Oncology Educational Committee Working Group for its medical oncology certification approval program with 13 ESMO-MORA category 1 points.

Accreditation requested to the "Consell Català de Formació Continuada de les Professions Sanitàries"

Supporting Companies

AstraZeneca · Lilly · Roche

Amgen · Bayer Schering Pharma · Boehringer Ingelheim · GlaxoSmithKline · Merck Sharp & Dohme · Novartis · Pierre Fabre

These companies have no influence over the contents of the scientific program

Conference Secretariat

Doctaforum · Congresos y Reuniones Científicas
Monasterios de Suso y Yuso 34, 4-14-2 · 28049 Madrid
Tel.: +34 91 372 02 03 · Fax: +34 91 735 04 54
www.doctaforum.com/gecp